uniQure (NASDAQ:QURE) Trading 5.4% Higher – What’s Next?

uniQure (NASDAQ:QURE)’s stock price traded up 5.4% on Thursday . The stock traded as high as $12.62 and last traded at $12.75. 393,383 shares were traded during mid-day trading, a decline of 62% from the average session volume of 1,027,320 shares. The stock had previously closed at $12.09.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. StockNews.com raised shares of uniQure to a “sell” rating in a report on Wednesday, February 5th. The Goldman Sachs Group raised their target price on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 12th. Wells Fargo & Company cut their target price on uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Friday, February 28th. Royal Bank of Canada reiterated an “outperform” rating and set a $24.00 target price on shares of uniQure in a report on Tuesday, January 21st. Finally, Stifel Nicolaus lifted their price target on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, uniQure presently has an average rating of “Moderate Buy” and a consensus price target of $38.89.

uniQure Stock Up 3.5 %

The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm has a 50-day moving average of $14.69 and a two-hundred day moving average of $9.91. The stock has a market capitalization of $609.77 million, a price-to-earnings ratio of -2.52 and a beta of 0.38.

Insider Activity

In other news, CFO Christian Klemt sold 10,438 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $107,407.02. Following the sale, the chief financial officer now owns 217,730 shares in the company, valued at $2,240,441.70. This represents a 4.57 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Matthew C. Kapusta sold 26,727 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total value of $285,978.90. Following the transaction, the chief executive officer now directly owns 571,188 shares in the company, valued at $6,111,711.60. The trade was a 4.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 96,044 shares of company stock valued at $1,001,040. Insiders own 4.74% of the company’s stock.

Institutional Investors Weigh In On uniQure

A number of large investors have recently bought and sold shares of QURE. Point72 Asset Management L.P. boosted its stake in shares of uniQure by 336.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after purchasing an additional 752,889 shares during the last quarter. Walleye Capital LLC purchased a new position in uniQure in the third quarter valued at about $444,000. FMR LLC boosted its position in uniQure by 8,056.6% during the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock worth $1,728,000 after purchasing an additional 346,274 shares during the period. Sanders Morris Harris LLC grew its position in shares of uniQure by 50.0% in the fourth quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock valued at $1,803,000 after purchasing an additional 34,034 shares in the last quarter. Finally, Franklin Resources Inc. purchased a new position in uniQure during the third quarter worth about $7,360,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.